Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Tai Sun | - |
dc.contributor.author | Kim, Hye-Ryoun | - |
dc.contributor.author | Koh, Jae Soo | - |
dc.contributor.author | Jang, Seung Hun | - |
dc.contributor.author | Hwang, Yong Il | - |
dc.contributor.author | Il Yoon, Ho | - |
dc.contributor.author | Chung, Jin-Haeng | - |
dc.contributor.author | Kim, Cheol Hyeon | - |
dc.contributor.author | Kim, Sung-Soo | - |
dc.contributor.author | Kim, Woo Sung | - |
dc.contributor.author | Jo, Jungmin | - |
dc.contributor.author | Lee, Jae Cheol | - |
dc.contributor.author | Choi, Chang-Min | - |
dc.date.accessioned | 2022-07-16T01:55:03Z | - |
dc.date.available | 2022-07-16T01:55:03Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2014-11 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/158622 | - |
dc.description.abstract | Objectives: Although adjuvant platinum-based chemotherapy improves survival in completely resected non-small cell lung cancer (NSCLC), its effect is limited. We evaluated whether the expression of heat shock protein 70 (Hsp70) is associated with clinical outcomes in patients with completely resected NSCLC who were treated with or without adjuvant platinum-based chemotherapy. Patients and methods: Patients who underwent curative resection for NSCLC and diagnosed as stage IIA through IIIA were included. Immunohistochemical staining for Hsp70 was performed on surgical specimens and survival rates were compared by Hsp70 expression and adjuvant platinum-based chemotherapy. Results: Of 327 enrolled patients, Hsp70 expression was positive in 220 (67.3%). For patients who did not receive adjuvant chemotherapy, Hsp70 expression did not significantly affect survival. However, for patients who received adjuvant chemotherapy, those with Hsp70-positive tumors had a longer disease-free survival outcome than cases with Hsp70-negative tumors (not reached vs. 27.3 months; P=. 0.002), although there was no significant difference in overall survival (97.0 vs. 58.9 months, P=. 0.080). In the adjuvant chemotherapy group, multivariate modeling showed that patients with Hsp70-postitive tumors had a lower risk of recurrence and death after adjusting for age, sex, performance status, pathologic stage, and histological type (disease-free survival: adjusted hazard ratio, 0.537; 95% CI, 0.362-0.796; P=. 0.002; overall survival: adjusted hazard ratio, 0.663; 95% CI, 0.419-1.051; P=. 0.080). Conclusion: Hsp70 is a positive predictive factor in completely resected NSCLC with received platinum-based adjuvant chemotherapy. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.title | Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Tai Sun | - |
dc.identifier.doi | 10.1016/j.lungcan.2014.08.009 | - |
dc.identifier.scopusid | 2-s2.0-84908399110 | - |
dc.identifier.wosid | 000344438400026 | - |
dc.identifier.bibliographicCitation | LUNG CANCER, v.86, no.2, pp.262 - 267 | - |
dc.relation.isPartOf | LUNG CANCER | - |
dc.citation.title | LUNG CANCER | - |
dc.citation.volume | 86 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 262 | - |
dc.citation.endPage | 267 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.subject.keywordPlus | HEAT-SHOCK PROTEINS | - |
dc.subject.keywordPlus | VINORELBINE PLUS CISPLATIN | - |
dc.subject.keywordPlus | DNA-REPAIR | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | ERCC1 | - |
dc.subject.keywordAuthor | Adjuvant chemotherapy | - |
dc.subject.keywordAuthor | Biologic markers | - |
dc.subject.keywordAuthor | Heat shock protein 70 | - |
dc.subject.keywordAuthor | Non-small cell lung cancer | - |
dc.subject.keywordAuthor | Survival analysis | - |
dc.subject.keywordAuthor | Treatment outcome | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0169500214003511?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.